Benjamin Shepherd
Focusing on Competitiveness
This fund will allow you to participate in the booming commercial real estate market.
Affirming Profitability
Obamacare almost guarantees higher profits for most of the health care industry, a sector in which this fund is deeply vested.
Into the Breach
Put aside the alarmist headlines about hacking incidents. The payment processing industry has several tailwinds behind it.
A Rebound in Treasuries
With rates near historic lows, this fund may prove valuable for investors against inevitable rising rates.
Technology Boom Redux
Barring a severe global economic disruption, semiconductor manufacturers should continue to benefit from booming chip demand this year.
Death of a Founder
The unfortunate passing of this fund's manager raises questions about whether this fund will be able to maintain its track record of success.
The Drug Approval Gauntlet
Promising drug start-ups beckon investors with their siren’s call, but your best bet is to stick with established pharmaceutical firms.
The Bulls May Run
This bond fund offers piece of mind in a volatile market.
Biotech Gets Personal
The rise of personalized medicine, which uses genetic information to tailor drug therapy regimens for individuals, promises better treatment outcomes for patients and higher profits for the biotech industry.
Building Expectations
By pursuing a conservative strategy in a riskier segment of the bond market, this fund has outperformed the majority of its peers over the past five years.











